Drugs / CD19x22 CAR T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06559189 | Sep 2024 → Dec 2028 expected | B-cell acute lymphoblastic leukemia | University of Colorado, Denver | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19x22 CAR T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06559189 ↗ |
| Modality | Cell therapy | “The investigational product is an autologous, genetically modified CD19xCD22 CAR T cell product produced by the Gates Biomanufacturing Facility.” NCT06559189 ↗ |
| Target | CD19 | “novel bispecific CD19/CD22-directed CAR T cell product (CD19x22)” NCT06559189 ↗ |
| Target | CD22 | “novel bispecific CD19/CD22-directed CAR T cell product (CD19x22)” NCT06559189 ↗ |